Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

Conclusion: Plin (20 mg/m2), an agent with anticancer activity for MM and NSCLC, mobilized CD34+ cells to clinically relevant blood counts in the vast majority of pts, through a MoA different from G-CSF or Pler. The CD34+ cell counts with Plin in the HCT setting is likely to be higher than observed in this CIN study, since concomitant myelosuppressive Doc was used with Plin. Furthermore CD34+ cell counts after D8 are likely to increase further with Plin, but this was not measured in this study. Based on current data evidence, Plin has the potential to become a viable option for the mobilization of CD34+ cells from the bone marrow prior to HCT, in particular in pts failing to respond to G-CSF or G-CSF/Pler.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 711. Cell Collection and Processing: Poster I Source Type: research